Northsea Therapeutics

Resalis Therapeutics

This company develops non-coding RNA therapies to treat metabolic disorders, including obesity and fatty liver disease, for patients with unmet medical needs.

Akero Therapeutics

This company develops metabolic disease treatments for patients with metabolic dysfunction-associated steatohepatitis and other liver conditions.

Mighty Therapeutics

This company develops mitochondrial-targeted therapies for patients with rare genetic conditions like Barth syndrome and common age-related diseases.

DTX Pharma

This biotechnology firm develops RNA-based therapeutics for patients with rare neuromuscular and central nervous system disorders using a proprietary fatty acid delivery platform.

Marea Therapeutics

This biotechnology company develops medicines for cardiometabolic and cardioendocrine diseases using human genetic data for patients with unmet medical needs.

Forth Therapeutics

This biotechnology company develops precision therapeutics for patients with organ fibrosis using a multi-omic discovery platform and human liver disease datasets.

Mereo BioPharma

The company develops clinical-stage therapies for patients with rare diseases, including osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.

Scenic Biotech

This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.